PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation

PAQ Therapeutics Launches with $30 Million Series A
to Develop Novel Therapies through Autophagy-Dependent Degradation

ATTEC: a potential new approach to target proteinopathies

Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds